OncoCyte (OCX): תחזית צמיחת רווח נקי למניה לשנה הבאה

OncoCyte Corporation (OCX) is scaling sales through the licensing of Determa kits, bypassing the need for laboratory expansion. Liquid biopsy provides a competitive advantage by simplifying cancer diagnostics via blood tests. However, low test volumes are constraining operating leverage due to high costs. Regarding the modeled EPS growth for the next fiscal year, this chart on GURU.Markets shows that the value of 0.70 expresses the metric level.

A steady patient flow, driven by the integration of genetic tests into annual clinic check-ups, creates a foundation for predictable revenue for OncoCyte Corporation (OCX). Assessing this stability via the consensus EPS n+1 forecast chart reflects the aggregate analyst expectations for earnings per share, where an upward trend confirms the scalability of the business model, while a decline signals risks of earnings shortfalls.